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1 Introduction
During the past three decades, catheter and surgical ablation of
atrial fibrillation (AF) have evolved from investigational pro-
cedures to their current role as effective treatment options for
patients with AF. Surgical ablation of AF, using either stan-
dard, minimally invasive, or hybrid techniques, is available in
most major hospitals throughout the world. Catheter ablation
of AF is even more widely available, and is now the most
commonly performed catheter ablation procedure.
In 2007, an initial Consensus Statement on Catheter and
Surgical AF Ablation was developed as a joint effort of the
Heart Rhythm Society (HRS), the European Heart Rhythm
Association (EHRA), and the European Cardiac Arrhythmia
Society (ECAS) [1]. The 2007 document was also developed
in collaboration with the Society of Thoracic Surgeons (STS)
and the American College of Cardiology (ACC). This
Consensus Statement on Catheter and Surgical AF Ablation
was rewritten in 2012 to reflect the many advances in AF
ablation that had occurred in the interim [2]. The rate of ad-
vancement in the tools, techniques, and outcomes of AF ab-
lation continue to increase as enormous research efforts are
focused on the mechanisms, outcomes, and treatment of AF.
For this reason, the HRS initiated an effort to rewrite and
update this Consensus Statement. Reflecting both the world-
wide importance of AF, as well as the worldwide performance
of AF ablation, this document is the result of a joint partner-
ship between the HRS, EHRA, ECAS, the Asia Pacific Heart
Rhythm Society (APHRS), and the Latin American Society of
Cardiac Stimulation and Electrophysiology (Sociedad
Latinoamericana de Estimulación Cardíaca y Electrofisiología
[SOLAECE]). The purpose of this 2017 Consensus Statement
is to provide a state-of-the-art review of the field of catheter and
surgical ablation of AF and to report the findings of a
writing group, convened by these five international so-
cieties. The writing group is charged with defining the
indications, techniques, and outcomes of AF ablation
procedures. Included within this document are recom-
mendations pertinent to the design of clinical trials in
the field of AF ablation and the reporting of outcomes,
including definitions relevant to this topic.
The writing group is composed of 60 experts representing 11
organizations: HRS, EHRA, ECAS, APHRS, SOLAECE, STS,
ACC, American Heart Association (AHA), Canadian Heart
Rhythm Society (CHRS), Japanese Heart Rhythm Society
(JHRS), and Brazilian Society of Cardiac Arrhythmias
(Sociedade Brasileira de Arritmias Cardíacas [SOBRAC]). All
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the members of the writing group, as well as peer reviewers of
the document, have provided disclosure statements for all rela-
tionships that might be perceived as real or potential conflicts of
interest. All author and peer reviewer disclosure information is
provided in Appendix ATable 14 and Appendix B Table 15.
In writing a consensus document, it is recognized that
consensus does not mean that there was complete agreement
among all the writing group members. Surveys of the entire
writing group were used to identify areas of consensus
concerning performance of AF ablation procedures and to
develop recommendations concerning the indications for
catheter and surgical AF ablation. These recommendations
were systematically balloted by the 60 writing group members
and were approved by a minimum of 80% of these members.
The recommendations were also subject to a 1-month public
comment period. Each partnering and collaborating organiza-
tion then officially reviewed, commented on, edited, and en-
dorsed the final document and recommendations.
The grading system for indication of class of evidence level
was adapted based on that used by the ACC and the AHA [3,
4]. It is important to state, however, that this document is not a
guideline. The indications for catheter and surgical ablation of
AF, as well as recommendations for procedure performance,
are presented with a Class and Level of Evidence (LOE) to be
consistent with what the reader is familiar with seeing in guide-
line statements. A Class I recommendation means that the ben-
efits of the AF ablation procedure markedly exceed the risks,
and that AF ablation should be performed; a Class IIa recom-
mendation means that the benefits of an AF ablation procedure
exceed the risks, and that it is reasonable to perform AF abla-
tion; a Class IIb recommendation means that the benefit of AF
ablation is greater or equal to the risks, and that AF ablation
may be considered; and a Class III recommendation means that
AF ablation is of no proven benefit and is not recommended.
The writing group reviewed and ranked evidence
supporting current recommendations with the weight of evi-
dence ranked as Level A if the data were derived from high-
quality evidence frommore than one randomized clinical trial,
meta-analyses of high-quality randomized clinical trials, or
one or more randomized clinical trials corroborated by high-
quality registry studies. The writing group ranked available
evidence as Level B-R when there was moderate-quality evi-
dence from one or more randomized clinical trials, or meta-
analyses of moderate-quality randomized clinical trials. Level
B-NRwas used to denote moderate-quality evidence from one
or more well-designed, well-executed nonrandomized studies,
observational studies, or registry studies. This designation was
also used to denote moderate-quality evidence from meta-
analyses of such studies. Evidence was ranked as Level C-
LD when the primary source of the recommendation was ran-
domized or nonrandomized observational or registry studies
with limitations of design or execution, meta-analyses of such
studies, or physiological or mechanistic studies of human
subjects. Level C-EO was defined as expert opinion based
on the clinical experience of the writing group.
Despite a large number of authors, the participation of sev-
eral societies and professional organizations, and the attempts of
the group to reflect the current knowledge in the field adequate-
ly, this document is not intended as a guideline. Rather, the
group would like to refer to the current guidelines on AF man-
agement for the purpose of guiding overall AF management
strategies [5, 6]. This consensus document is specifically fo-
cused on catheter and surgical ablation of AF, and summarizes
the opinion of the writing groupmembers based on an extensive
literature review as well as their own experience. It is directed to
all health care professionals who are involved in the care of
patients with AF, particularly those who are caring for patients
who are undergoing, or are being considered for, catheter or
surgical ablation procedures for AF, and those involved in re-
search in the field of AF ablation. This statement is not intended
to recommend or promote catheter or surgical ablation of AF.
Rather, the ultimate judgment regarding care of a particular
patient must be made by the health care provider and the patient
in light of all the circumstances presented by that patient.
The main objective of this document is to improve patient
care by providing a foundation of knowledge for those in-
volved with catheter ablation of AF. A second major objective
is to provide recommendations for designing clinical trials and
reporting outcomes of clinical trials of AF ablation. It is rec-
ognized that this field continues to evolve rapidly. As this
document was being prepared, further clinical trials of catheter
and surgical ablation of AF were under way.
2 Definitions, mechanisms, and rationale for AF
ablation
This section of the document provides definitions for use in
the diagnosis of AF. This section also provides an in-depth
review of the mechanisms of AF and rationale for catheter and
surgical AF ablation (Table 1, Figs. 1, 2, 3, 4, 5, and 6).
3 Modifiable risk factors for AF and impact
on ablation
Management of patients with AF has traditionally consisted of
three main components: (1) anticoagulation for stroke prevention;
(2) rate control; and (3) rhythm control. With the emergence of
large amounts of data, which have both defined and called atten-
tion to the interaction between modifiable risk factors and the
development ofAF and outcomes ofAFmanagement,we believe
it is time to include risk factor modification as the fourth pillar of
AF management. This section of the document reviews the link
between modifiable risk factors and both the development of AF
and their impacts on the outcomes of AF ablation.
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Fig. 1 Anatomical drawings of
the heart relevant to AF ablation.
This series of drawings shows the
heart and associated relevant
structures from four different
perspectives relevant to AF
ablation. This drawing includes
the phrenic nerves and the
esophagus. a The heart viewed
from the anterior perspective. b
The heart viewed from the right
lateral perspective. c The heart
viewed from the left lateral
perspective. d The heart viewed
from the posterior perspective. e
The left atrium viewed from the
posterior perspective. Illustration:
Tim Phelps © 2017 Johns
Hopkins University, AAM
Table 1 Atrial fibrillation
definitions AF episode AnAF episode is defined as AF that is documented by ECGmonitoring or intracardiac
electrogram monitoring and has a duration of at least 30 s, or if less than 30 s, is
present throughout the ECG monitoring tracing. The presence of subsequent
episodes of AF requires that sinus rhythm be documented by ECG monitoring
between AF episodes.
Chronic AF Chronic AF has variable definitions and should not be used to describe populations of
AF patients undergoing AF ablation.
Early persistent AF Early persistent AF is defined as AF that is sustained beyond 7 days but is less than 3
months in duration.
Lone AF LoneAF is a historical descriptor that is potentially confusing and should not be used to
describe populations of patients with AF undergoing AF ablation.
Long-standing
persistent AF
Long-standing persistent AF is defined as continuous AF of greater than 12 months’
duration.
Paroxysmal AF Paroxysmal AF is defined as AF that terminates spontaneously or with intervention
within 7 days of onset.
Permanent AF Permanent AF is defined as the presence of AF that is accepted by the patient and
physician, and for which no further attempts to restore or maintain sinus rhythm will
be undertaken. The term permanent AF represents a therapeutic attitude on the part
of the patient and physician rather than an inherent pathophysiological attribute of
AF. The term permanent AF should not be used within the context of a rhythm
control strategy with antiarrhythmic drug therapy or AF ablation.
Persistent AF Persistent AF is defined as continuous AF that is sustained beyond 7 days.
Silent AF Silent AF is defined as asymptomatic AF diagnosed with an opportune ECG or rhythm
strip.
AF atrial fibrillation, ECG electrocardiogram
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4 Indications
Shown in Table 2, and summarized in Figs. 7 and 8 of this
document, are the Consensus Indications for Catheter and
Surgical Ablation of AF. As outlined in the introduction sec-
tion of this document, these indications are stratified as Class
I, Class IIa, Class IIb, and Class III indications. The evi-
dence supporting these indications is provided, as well as
a selection of the key references supporting these levels of
evidence. In making these recommendations, the writing
group considered the body of published literature that has
defined the safety and efficacy of catheter and surgical
Fig. 2 This figure includes six CT or MR images of the left atrium and
pulmonary veins viewed from the posterior perspective. Common and
uncommon variations in PV anatomy are shown. a Standard PV
anatomy with 4 distinct PV ostia. b Variant PV anatomy with a right
common and a left common PV. c Variant PV anatomy with a left
common PV with a short trunk and an anomolous PV arising from the
right posterior left atrial wall. d and eVariant PVanatomy with a common
left PV with a long trunk. f Variant PV anatomy with a massive left
common PV
Fig. 3 Schematic drawing
showing various hypotheses and
proposals concerning the
mechanisms of atrial fibrillation.
aMultiple wavelets hypothesis. b
Rapidly discharging automatic
foci. c Single reentrant circuit
with fibrillatory conduction. d
Functional reentry resulting from
rotors or spiral waves. e AF
maintenance resulting from
dissociation between epicardial
and endocardial layers, with
mutual interaction producing
multiplying activity that
maintains the arrhythmia
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Fig. 4 Structure and mechanisms of atrial fibrillation. a Schematic
drawing of the left and right atria as viewed from the posterior
perspective. The extension of muscular fibers onto the PVs can be
appreciated. Shown in yellow are the five major left atrial autonomic
ganglionic plexi (GP) and axons (superior left GP, inferior left GP,
anterior right GP, inferior right GP, and ligament of Marshall). Shown
in blue is the coronary sinus, which is enveloped by muscular fibers that
have connections to the atria. Also shown in blue is the vein and ligament
of Marshall, which travels from the coronary sinus to the region between
the left superior PV and the left atrial appendage. b The large and small
reentrant wavelets that play a role in initiating and sustaining AF. c The
common locations of PV (red) and also the common sites of origin of
non-PV triggers (shown in green). d Composite of the anatomic and
arrhythmic mechanisms of AF. Adapted with permission from Calkins
et al. Heart Rhythm 2012; 9:632–696.e21 [2]
Fig. 5 Schematic drawing
showing mechanisms of atrial
flutter and atrial tachycardia. a
Isthmus-dependent reverse
common (clockwise) atrial flutter.
b Isthmus-dependent common
(counter clockwise) atrial flutter. c
Focal atrial tachycardia with
circumferential spread of
activation of the atria (can arise
from multiple sites within the left
and right atrium). d
Microreentrant atrial tachycardia
with circumferential spread of
activation of the atria. e Perimitral
atrial flutter. f Roof-dependent
atrial flutter
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ablation of AF. Also considered in these recommendations
is the personal lifetime experience in the field of each of
the writing group members. Both the number of clinical
trials and the quality of these trials were considered. In
considering the class of indications recommended by this
writing group, it is important to keep several points in
mind. First, these classes of indications only define the
indications for catheter and surgical ablation of AF when
performed by an electrophysiologist or a surgeon who has
received appropriate training and/or who has a certain
level of experience and is performing the procedure in
an experienced center (Section 11). Catheter and surgical
ablation of AF are highly complex procedures, and a care-
ful assessment of the benefit and risk must be considered
for each patient. Second, these indications stratify patients
based only on the type of AF and whether the procedure
is being performed prior to or following a trial of one or
more Class I or III antiarrhythmic medications. This doc-
ument for the first time includes indications for catheter
ablation of select asymptomatic patients. As detailed in
Section 9, there are many other additional clinical and
imaging-based variables that can be used to further define
the efficacy and risk of ablation in a given patient. Some
of the variables that can be used to define patients in
whom a lower success rate or a higher complication rate
can be expected include the presence of concomitant heart
disease, obesity, sleep apnea, left atrial (LA) size, patient
age and frailty, as well as the duration of time the patient
has been in continuous AF. Each of these variables needs
to be considered when discussing the risks and benefits of
AF ablation with a particular patient. In the presence of
substantial risk or anticipated difficulty of ablation, it
could be more appropriate to use additional antiarrhyth-
mic drug (AAD) options, even if the patient on face value
Fig. 6 Schematic of common lesion sets employed in AF ablation. a The
circumferential ablation lesions that are created in a circumferential
fashion around the right and the left PVs. The primary endpoint of this
ablation strategy is the electrical isolation of the PVmusculature. b Some
of the most common sites of linear ablation lesions. These include a “roof
line” connecting the lesions encircling the left and/or right PVs, a “mitral
isthmus” line connecting the mitral valve and the lesion encircling the left
PVs at the end of the left inferior PV, and an anterior linear lesion
connecting either the “roof line” or the left or right circumferential
lesion to the mitral annulus anteriorly. A linear lesion created at the
cavotricuspid isthmus is also shown. This lesion is generally placed in
patients who have experienced cavotricuspid isthmus-dependent atrial
flutter clinically or have it induced during EP testing. c Similar to 6B,
but also shows additional linear ablation lesions between the superior and
inferior PVs resulting in a figure of eight lesion sets as well as a posterior
inferior line allowing for electrical isolation of the posterior left atrial wall.
An encircling lesion of the superior vena cava (SVC) directed at electrical
isolation of the SVC is also shown. SVC isolation is performed if focal
firing from the SVC can be demonstrated. A subset of operators
empirically isolates the SVC. d Representative sites for ablation when
targeting rotational activity or CFAEs are targeted. Modified with
permission from Calkins et al. Heart Rhythm 2012; 9:632–696.e21 [2]
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Table 2 Indications for catheter (A and B) and surgical (C, D, and E) ablation of atrial fibrillation
Recommendation Class LOE References
Indications for catheter ablation of atrial fibrillation
A. Indications for catheter ablation of atrial fibrillation
Symptomatic AF
refractory or intolerant to at
least one Class I or III
antiarrhythmic medication
Paroxysmal: Catheter ablation is recommended. I A [7–18]
Persistent: Catheter ablation is reasonable. IIa B-NR [8, 16–26]
Long-standing persistent: Catheter ablation may be
considered.
IIb C-LD [8, 16–26]
Symptomatic AF prior to
initiation of antiarrhythmic
therapy with a Class I or III
antiarrhythmic medication
Paroxysmal: Catheter ablation is reasonable. IIa B-R [27–35]
Persistent: Catheter ablation is reasonable. IIa C-EO
Long-standing persistent: Catheter ablation may be
considered.
IIb C-EO
B. Indications for catheter atrial fibrillation ablation in populations of patients not well represented in clinical trials
Congestive heart failure It is reasonable to use similar indications for AF
ablation in selected patients with heart failure as in
patients without heart failure.
IIa B-R [36–52]
Older patients (>75 years
of age)
It is reasonable to use similar indications for AF
ablation in selected older patients with AF as in
younger patients.
IIa B-NR [53–59]
Hypertrophic
cardiomyopathy
It is reasonable to use similar indications for AF
ablation in selected patients with HCM as in patients
without HCM.
IIa B-NR [60–62]
Young patients (<45
years of age)
It is reasonable to use similar indications for AF
ablation in young patients with AF (<45 years of
age) as in older patients.
IIa B-NR [63, 64]
Tachy-brady syndrome It is reasonable to offer AF ablation as an alternative to
pacemaker implantation in patients with tachy-brady
syndrome.
IIa B-NR [33–35]
Athletes with AF It is reasonable to offer high-level athletes AF as
first-line therapy due to the negative effects of
medications on athletic performance.
IIa C-LD [27, 28, 65]
Asymptomatic AF∗∗ Paroxysmal: Catheter ablation may be considered in
select patients.∗∗
IIb C-EO [66, 67]
Persistent: Catheter ablation may be considered in
select patients.
IIb C-EO [68]
Indications for surgical ablation of atrial fibrillation
C. Indications for concomitant open (such as mitral valve) surgical ablation of atrial fibrillation
Symptomatic AF
refractory or intolerant to at
least one Class I or III
antiarrhythmic medication
Paroxysmal: Surgical ablation is recommended. I B-NR [69–82]
Persistent: Surgical ablation is recommended. I B-NR [69–82]
Long-standing persistent: Surgical ablation is
recommended.
I B-NR [69–82]
Symptomatic AF prior to
initiation of antiarrhythmic
therapy with a Class I or III
antiarrhythmic medication
Paroxysmal: Surgical ablation is recommended. I B-NR [69–82]
Persistent: Surgical ablation is recommended. I B-NR [69–82]
Long-standing persistent: Surgical ablation is
recommended.
I B-NR [69–82]
D. Indications for concomitant closed (such as CABG and AVR) surgical ablation of atrial fibrillation
Symptomatic AF
refractory or intolerant to at
least one Class I or III
antiarrhythmic medication
Paroxysmal: Surgical ablation is recommended. I B-NR [83–88]
Persistent: Surgical ablation is recommended. I B-NR [83–88]
Long-standing persistent: Surgical ablation is
recommended.
I B-NR [83–88]
Symptomatic AF prior to
initiation of antiarrhythmic
therapy with a Class I or III
antiarrhythmic medication
Paroxysmal: Surgical ablation is reasonable. IIa B-NR [83–88]
Persistent: Surgical ablation is reasonable. IIa B-NR [83–88]
Long-standing persistent: Surgical ablation is
reasonable.
IIa B-NR [83–88]
E. Indications for stand-alone and hybrid surgical ablation of atrial fibrillation
Symptomatic AF
refractory or intolerant to at
least one Class I or III
antiarrhythmic medication
Paroxysmal: Stand-alone surgical ablation can be
considered for patients who have failed one or more
attempts at catheter ablation and also for those who
are intolerant or refractory to antiarrhythmic drug
IIb B-NR [83–85, 89–103]
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might present with a Class I or IIa indication for ablation.
Third, it is important to consider patient preference and
values. Some patients are reluctant to consider a major
procedure or surgery and have a strong preference for a
pharmacological approach. In these patients, trials of an-
tiarrhythmic agents including amiodarone might be pre-
ferred to catheter ablation. On the other hand, some pa-
tients prefer a nonpharmacological approach. Fourth, it is
important to recognize that some patients early in the
course of their AF journey might have only infrequent
episodes for many years and/or could have AF that is
responsive to well-tolerated AAD therapy. And finally, it
is important to bear in mind that a decision to perform
catheter or surgical AF ablation should only be made after
a patient carefully considers the risks, benefits, and alter-
natives to the procedure.
5 Strategies, techniques, and endpoints
The writing group recommendations for techniques to be used
for ablation of persistent and long-standing persistent AF
(Table 3), adjunctive ablation strategies, nonablative strategies
to improve outcomes of AF ablation, and endpoints for abla-
tion of paroxysmal, persistent, and long-standing persistent
AF are covered in this section. A schematic overview of com-
mon lesion sets created during an AF ablation procedure is
shown in Fig. 6.
6 Technology and tools
This section of the consensus statement provides an up-
date on many of the technologies and tools that are
employed for AF ablation procedures. It is important
to recognize that this is not a comprehensive listing
and that new technologies, tools, and approaches are
being developed. It is also important to recognize that
Fig. 7 Indications for catheter ablation of symptomatic atrial fibrillation.
Shown in this figure are the indications for catheter ablation of
symptomatic paroxysmal, persistent, and long-standing persistent AF.
The Class for each indication based on whether ablation is performed
after failure of antiarrhythmic drug therapy or as first-line therapy is
shown. Please refer to Table 2B and the text for the indications for
catheter ablation of asymptomatic AF
Table 2 (continued)
Recommendation Class LOE References
therapy and prefer a surgical approach, after review
of the relative safety and efficacy of catheter ablation
versus a stand-alone surgical approach.
Persistent: Stand-alone surgical ablation is reasonable
for patients who have failed one or more attempts at
catheter ablation and also for those patients who
prefer a surgical approach after review of the relative
safety and efficacy of catheter ablation versus a
stand-alone surgical approach.
IIa B-NR [83–85, 89–103]
Long-standing persistent: Stand-alone surgical ablation
is reasonable for patients who have failed one or
more attempts at catheter ablation and also for those
patients who prefer a surgical approach after review
of the relative safety and efficacy of catheter ablation
versus a stand-alone surgical approach.
IIa B-NR [83–85, 89–103]
It might be reasonable to apply the indications for
stand-alone surgical ablation described above to
patients being considered for hybrid surgical AF
ablation.
IIb C-EO [103–108]
AF atrial fibrillation, LOE Level of Evidence, HCM hypertrophic cardiomyopathy
∗∗A decision to perform AF ablation in an asymptomatic patient requires additional discussion with the patient because the potential benefits of the
procedure for the patient without symptoms are uncertain
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radiofrequency (RF) energy is the dominant energy
source available for ablation of typical and atypical atri-
al flutter (AFL). Although cryoablation is a commonly
employed tool for AF ablation, it is not well suited for
ablation of typical or atypical AFL. Other energy
sources and tools are available in some parts of the
world and/or are in various stages of development and/
or clinical investigation. Shown in Fig. 9 are schematic
drawings of AF ablation using point-by-point RF energy
(Fig. 9a) and AF ablation using the cryoballoon (CB)
system (Fig. 9b).
7 Technical aspects of ablation to maximize safety
and anticoagulation
Anticoagulation strategies pre-, during, and postcatheter abla-
tion of AF (Table 4); signs and symptoms of complications
that can occur within the first several months following abla-
tion (Table 5); anesthesia or sedation during ablation; and
approaches to minimize risk of an atrial esophageal fistula
are discussed in this section.
8 Follow-up considerations
AF ablation is an invasive procedure that entails risks, most of
which are present during the acute procedural period.
However, complications can also occur in the weeks or
months following ablation. Recognizing common symptoms
after AF ablation and distinguishing those that require urgent
evaluation and referral to an electrophysiologist is an impor-
tant part of follow-up after AF ablation. The success of AF
ablation is based in large part on freedom from AF recurrence
based on ECG monitoring. Arrhythmia monitoring can be
performed with the use of noncontinuous or continuous
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Paroxysmal 
AF
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Surgical 
Ablation
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Drugs
AA
Drugs
Persistent 
AF
Long-standing 
Persistent AF
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Fig. 8 Indications for surgical ablation of atrial fibrillation. Shown in this
figure are the indications for surgical ablation of paroxysmal, persistent,
and long-standing persistent AF. The Class for each indication based on
whether ablation is performed after failure of antiarrhythmic drug therapy
or as first-line therapy is shown. The indications for surgical AF ablation
are divided into whether the AF ablation procedure is performed
concomitantly with an open surgical procedure (such as mitral valve
replacement), a closed surgical procedure (such as coronary artery
bypass graft surgery), or as a stand-alone surgical AF ablation
procedure performed solely for treatment of atrial fibrillation
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Table 3 Atrial fibrillation ablation: strategies, techniques, and endpoints
Recommendation Class LOE References
PV isolation by catheter
ablation
Electrical isolation of the PVs is recommended during
all AF ablation procedures.
I A [7–16, 19–26, 109]
Achievement of electrical isolation requires, at a
minimum, assessment and demonstration of
entrance block into the PV.
I B-R [7–16, 19–26, 109]
Monitoring for PV reconnection for 20 min following
initial PV isolation is reasonable.
IIa B-R [9, 110–120]
Administration of adenosine 20 min following initial
PV isolation using RF energy with reablation if PV
reconnection might be considered.
IIb B-R [109, 111–114, 120–128]
Use of a pace-capture (pacing along the ablation line)
ablation strategy may be considered.
IIb B-R [129–133]
Demonstration of exit block may be considered. IIb B-NR [134–139]
Ablation strategies to be
considered for use in
conjunction with PV
isolation
If a patient has a history of typical atrial flutter or
typical atrial flutter is induced at the time of AF
ablation, delivery of a cavotricuspid isthmus linear
lesion is recommended.
I B-R [140–143]
If linear ablation lesions are applied, operators should
use mapping and pacing maneuvers to assess for line
completeness.
I C-LD [19, 141–149]
If a reproducible focal trigger that initiates AF is
identified outside the PVostia at the time of an AF
ablation procedure, ablation of the focal trigger
should be considered.
IIa C-LD [150–161]
When performing AF ablation with a force-sensing RF
ablation catheter, a minimal targeted contact force of
5 to 10 g is reasonable.
IIa C-LD [13, 14, 128, 162–178]
Posterior wall isolation might be considered for initial
or repeat ablation of persistent or long-standing
persistent AF.
IIb C-LD [21, 179–185]
Administration of high-dose isoproterenol to screen for
and then ablate non-PV triggers may be considered
during initial or repeat AF ablation procedures in
patients with paroxysmal, persistent, or
long-standing persistent AF.
IIb C-LD [150–161]
DF-based ablation strategy is of unknown usefulness
for AF ablation.
IIb C-LD [186–193]
The usefulness of creating linear ablation lesions in the
right or left atrium as an initial or repeat ablation
strategy for persistent or long-standing persistent AF
is not well established.
IIb B-NR [19, 20, 142, 145–149, 194–201]
The usefulness of linear ablation lesions in the absence
of macroreentrant atrial flutter is not well
established.
IIb C-LD [19, 20, 142, 145–149, 194–201]
The usefulness of mapping and ablation of areas of
abnormal myocardial tissue identified with voltage
mapping or MRI as an initial or repeat ablation
strategy for persistent or long-standing persistent AF
is not well established.
IIb B-R [179, 202–211]
The usefulness of ablation of complex fractionated
atrial electrograms as an initial or repeat ablation
strategy for persistent and long-standing persistent
AF is not well established.
IIb B-R [19, 20, 195–197, 212–220]
The usefulness of ablation of rotational activity as an
initial or repeat ablation strategy for persistent and
long-standing persistent AF is not well established.
IIb B-NR [221–241]
The usefulness of ablation of autonomic ganglia as an
initial or repeat ablation strategy for paroxysmal,
persistent, and long-standing persistent AF is not
well established.
IIb B-NR [19, 89, 242–259]
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Table 3 (continued)
Recommendation Class LOE References
Nonablation strategies to
improve outcomes
Weight loss can be useful for patients with AF,
including those who are being evaluated to undergo
an AF ablation procedure, as part of a
comprehensive risk factor management strategy.
IIa B-R [260–288]
It is reasonable to consider a patient's BMI when
discussing the risks, benefits, and outcomes of AF
ablation with a patient being evaluated for an AF
ablation procedure.
IIa B-R [260–288]
It is reasonable to screen for signs and symptoms of
sleep apnea when evaluating a patient for an AF
ablation procedure and to recommend a sleep
evaluation if sleep apnea is suspected.
IIa B-R [270, 276–278, 289–307]
Treatment of sleep apnea can be useful for patients with
AF, including those who are being evaluated to
undergo an AF ablation procedure.
IIa B-R [270, 276–278, 289–307]
The usefulness of discontinuation of antiarrhythmic
drug therapy prior to AF ablation in an effort to
improve long-term outcomes is unclear.
IIb C-LD [308–312]
The usefulness of initiation or continuation of
antiarrhythmic drug therapy during the postablation
healing phase in an effort to improve long-term
outcomes is unclear.
IIb C-LD [308–312]
Strategies to reduce the risks
of AF ablation
Careful identification of the PVostia is mandatory to
avoid ablation within the PVs.
I B-NR [313–335]
It is recommended that RF power be reduced when
creating lesions along the posterior wall near the
esophagus.
I C-LD [68, 336–365]
It is reasonable to use an esophageal temperature probe
during AF ablation procedures to monitor
esophageal temperature and help guide energy
delivery.
IIa C-EO [68, 336, 345, 365]
AF atrial fibrillation, LOE Level of Evidence, PV pulmonary vein, RF radiofrequency, MRI magnetic resonance imaging, BMI body mass index
Fig. 9 Schematic drawing showing catheter ablation of atrial fibrillation
using either RF energy or cryoballoon AF ablation. a Shows a typical
wide area lesion set created using RF energy. Ablation lesions are
delivered in a figure of eight pattern around the left and right PV veins.
Also shown is a linear cavotricuspid isthmus lesion created for ablation of
typical atrial flutter in a patient with a prior history of typical atrial flutter
or inducible isthmus-dependent typical atrial flutter at the time of
ablation. A multielectrode circular mapping catheter is positioned in the
left inferior PV. b Shows an ablation procedure using the cryoballoon
system. Ablation lesions have been created surrounding the right PVs,
and the cryoballoon ablation catheter is positioned in the left superior PV.
A through the lumen multielectrode circular mapping catheter is
positioned in the left superior PV. Illustration: Tim Phelps © 2017
Johns Hopkins University, AAM
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Table 4 Anticoagulation strategies: pre-, during, and postcatheter ablation of AF
Recommendation Class LOE References
Preablation For patients undergoing AF catheter ablation who have
been therapeutically anticoagulated with warfarin or
dabigatran, performance of the ablation procedure
without interruption of warfarin or dabigatran is
recommended.
I A [366–373]
For patients undergoing AF catheter ablation who have
been therapeutically anticoagulated with
rivaroxaban, performance of the ablation procedure
without interruption of rivaroxaban is
recommended.
I B-R [374]
For patients undergoing AF catheter ablation who have
been therapeutically anticoagulated with a NOAC
other than dabigatran or rivaroxaban, performance of
the ablation procedure without withholding a NOAC
dose is reasonable.
IIa B-NR [375]
Anticoagulation guidelines that pertain to
cardioversion of AF should be adhered to in patients
who present for an AF catheter ablation procedure.
I B-NR [5, 6]
For patients anticoagulated with a NOAC prior to AF
catheter ablation, it is reasonable to hold one to two
doses of the NOAC prior to AF ablation with
reinitiation postablation.
IIa B-NR [372, 376–380]
Performance of a TEE in patients who are in AF on
presentation for AF catheter ablation and who have
been receiving anticoagulation therapeutically for 3
weeks or longer is reasonable.
IIa C-EO [5, 6]
Performance of a TEE in patients who present for
ablation in sinus rhythm and who have not been
anticoagulated prior to catheter ablation is
reasonable.
IIa C-EO [5, 6]
Use of intracardiac echocardiography to screen for
atrial thrombi in patients who cannot undergo TEE
may be considered.
IIb C-EO [381–386]
During ablation Heparin should be administered prior to or immediately
following transseptal puncture during AF catheter
ablation procedures and adjusted to achieve and
maintain an ACT of at least 300 s.
I B-NR [369, 380–382, 387–393]
Administration of protamine following AF catheter
ablation to reverse heparin is reasonable.
IIa B-NR [394]
Postablation In patients who are not therapeutically anticoagulated
prior to catheter ablation of AF and in whom
warfarin will be used for anticoagulation
postablation, low molecular weight heparin or
intravenous heparin should be used as a bridge for
initiation of systemic anticoagulation with warfarin
following AF ablation.∗
I C-EO
Systemic anticoagulation with warfarin∗or a NOAC is
recommended for at least 2 months postcatheter
ablation of AF.
I C-EO [1, 2]
Adherence to AF anticoagulation guidelines is
recommended for patients who have undergone an
AF ablation procedure, regardless of the apparent
success or failure of the procedure.
I C-EO [5, 6]
Decisions regarding continuation of systemic
anticoagulation more than 2 months post ablation
should be based on the patient's stroke risk profile
and not on the perceived success or failure of the
ablation procedure.
I C-EO [5, 6]
In patients who have not been anticoagulated prior to
catheter ablation of AF or in whom anticoagulation
with a NOAC or warfarin has been interrupted prior
to ablation, administration of a NOAC 3 to 5 h after
IIa C-EO [372, 376–380]
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ECG monitoring tools (Table 6). This section also discusses
the important topics of AAD and non-AAD use prior to and
following AF ablation, the role of cardioversion, as well as the
indications for and timing of repeat AF ablation procedures.
9 Outcomes and efficacy
This section provides a comprehensive review of the out-
comes of catheter ablation of AF. Table 7 summarizes the
Table 4 (continued)
Recommendation Class LOE References
achievement of hemostasis is reasonable
postablation.
Patients in whom discontinuation of anticoagulation is
being considered based on patient values and
preferences should consider undergoing continuous
or frequent ECG monitoring to screen for AF
recurrence.
IIb C-EO
AF atrial fibrillation, LOE Level of Evidence, NOAC novel oral anticoagulant, TEE transesophageal electrocardiogram, ACT activated clotting time
∗Time in therapeutic range (TTR) should be > 65% – 70% on warfarin
Table 5 Signs and symptoms following AF ablation
Differential Suggested evaluation
Signs and symptoms of complications within a month postablation
Back pain Musculoskeletal, retroperitoneal hematoma Physical exam, CT imaging
Chest pain Pericarditis, pericardial effusion, coronary stenosis
(ablation related), pulmonary vein stenosis,
musculoskeletal (after cardioversion), worsening
reflux
Physical exam, chest X-ray, ECG, echocardiogram,
stress test, cardiac catheterization, chest CT
Cough Infectious process, bronchial irritation (mechanical,
cryoballoon), pulmonary vein stenosis
Physical exam, chest X-ray, chest CT
Dysphagia Esophageal irritation (related to transesophageal
echocardiography), atrioesophageal fistula
Physical exam, chest CT or MRI
Early satiety, nausea Gastric denervation Physical exam, gastric emptying study
Fever Infectious process, pericarditis, atrioesophageal fistula Physical exam, chest X-ray, chest CT, urinalysis,
laboratory blood work
Fever, dysphagia,
neurological symptoms
Atrial esophageal fistula Physical exam, laboratory blood work, chest CT or
MRI; avoid endoscopy with air insufflation
Groin pain at site of access Pseudoaneurysm, AV fistula, hematoma Ultrasound of the groin, laboratory blood work;
consider CT scan if ultrasound negative
Headache Migraine (related to anesthesia or transseptal access,
hemorrhagic stroke), effect of general anesthetic
Physical exam, brain imaging (MRI)
Hypotension Pericardial effusion/tamponade, bleeding, sepsis,
persistent vagal reaction
Echocardiography, laboratory blood work
Hemoptysis PV stenosis or occlusion, pneumonia Chest X-ray, chest CT or MR scan, VQ scan
Neurological symptoms Cerebral embolic event, atrial esophageal fistula Physical exam, brain imaging, chest CT or MRI
Shortness of breath Volume overload, pneumonia, pulmonary vein
stenosis, phrenic nerve injury
Physical exam, chest X-ray, chest CT, laboratory blood
work
Signs and symptoms of complications more than a month postablation
Fever, dysphagia,
neurological symptoms
Atrial esophageal fistula Physical exam, laboratory blood work, chest CT or
MRI; avoid endoscopy with air insufflation
Persistent cough, atypical
chest pain
Infectious process, pulmonary vein stenosis Physical exam, laboratory blood work, chest X-ray,
chest CT or MRI
Neurological symptoms Cerebral embolic event, atrial esophageal fistula Physical exam, brain imaging, chest CT or MRI
Hemoptysis PV stenosis or occlusion, pneumonia CT scan, VQ scan
AF atrial fibrillation, ECG electrocardiogram, CT computed tomography, MRI magnetic resonance imaging, VQ ventilation-perfusion
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main findings of the most important clinical trials in this field.
Outcomes of AF ablation in subsets of patients not well rep-
resented in these trials are reviewed. Outcomes for specific
ablation systems and strategies (CB ablation, rotational activ-
ity ablation, and laser balloon ablation) are also reviewed.
10 Complications
Catheter ablation of AF is one of the most complex interven-
tional electrophysiological procedures. AF ablation by its na-
ture involves catheter manipulation and ablation in the deli-
cate thin-walled atria, which are in close proximity to other
important organs and structures that can be impacted through
collateral damage. It is therefore not surprising that AF abla-
tion is associated with a significant risk of complications,
some of whichmight result in life-long disability and/or death.
This section reviews the complications associated with cathe-
ter ablation procedures performed to treat AF. The types and
incidence of complications are presented, their mechanisms
are explored, and the optimal approach to prevention and
treatment is discussed (Tables 8 and 9).
11 Training requirements
This section of the document outlines the training re-
quirements for those who wish to perform catheter ab-
lation of AF.
12 Surgical and hybrid AF ablation
Please refer to Table 2 and Fig. 8 presented earlier in this
Executive Summary.
13 Clinical trial design
Although there have been many advances made in the field of
catheter and surgical ablation of AF, there is still much to be
learned about the mechanisms of initiation and maintenance
of AF and how to apply this knowledge to the still-evolving
techniques of AF ablation. Although single-center, observa-
tional reports have dominated the early days of this field, we
are quickly moving into an era in which hypotheses are put
through the rigor of testing in well-designed, randomized,
Table 6 Types of ambulatory cardiac monitoring devices
Type of recorder Typical monitoring
duration
Continuous
recording
Event
recording
Auto
trigger
Unique features
Holter monitor 24–48 h, approximately
7–30 days
Yes Yes N/A Short term, provides quantitative data on arrhythmia
burden
Patch monitor 1–3 weeks Yes Yes N/A Intermediate term, can provide continuous data for up
to several weeks; improved patient compliance
without lead wires
External loop recorder 1 month Yes Yes Variable Good correlation between symptoms and even brief
arrhythmias
External nonloop recorder Months No Yes No May be used long term and intermittently; will not
capture very brief episodes
Smartphone monitor Indefinite No Yes No Provides inexpensive long-term intermittent
monitoring; dependent on patient compliance;
requires a smartphone
Mobile cardiac telemetry 30 days Yes Yes Yes Real time central monitoring and alarms; relatively
expensive
Implantable loop recorder Up to 3 years Yes Yes Yes Improved patient compliance for long-term use; not
able to detect 30-s episodes of AF due to detection
algorithm; presence of AF needs to be confirmed by
EGM review because specificity of detection
algorithm is imperfect; expensive
Pacemakers or ICDs with
atrial leads
Indefinite Yes Yes Yes Excellent AF documentation of burden and trends;
presence of AF needs to be confirmed by
electrogram tracing review because specificity of
detection algorithms is imperfect; expensive
Wearable multisensor
ECG monitors
Indefinite Yes Yes Yes ECG 3 leads, temp, heart rate, HRV, activity tracking,
respiratory rate, galvanic skin response
AF atrial fibrillation, ICD implantable cardioverter defibrillator, ECG electrocardiogram, HRV heart rate variability
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Table 8 Definitions of complications associated with AF ablation
Asymptomatic cerebral embolism Asymptomatic cerebral embolism is defined as an occlusion of a blood vessel in the brain due to
an embolus that does not result in any acute clinical symptoms. Silent cerebral embolism is
generally detected using a diffusion weighted MRI.
Atrioesophageal fistula An atrioesophageal fistula is defined as a connection between the atrium and the lumen of the
esophagus. Evidence supporting this diagnosis includes documentation of esophageal
erosion combined with evidence of a fistulous connection to the atrium, such as air emboli,
an embolic event, or direct observation at the time of surgical repair. A CTscan or MRI scan
is the most common method of documentation of an atrioesophageal fistula.
Bleeding Bleeding is defined as a major complication of AF ablation if it requires and/or is treated with
transfusion or results in a 20% or greater fall in hematocrit.
Bleeding following cardiac surgery Excessive bleeding following a surgical AF ablation procedure is defined as bleeding requiring
reoperation or ≥2 units of PRBC transfusion within any 24 h of the first 7 days following the
index procedure.
Cardiac perforation We recommend that cardiac perforation be defined together with cardiac tamponade. See
“Cardiac tamponade/perforation.”
Cardiac tamponade We recommend that cardiac tamponade be defined together with cardiac perforation. See
“Cardiac tamponade/perforation.”
Cardiac tamponade/perforation Cardiac tamponade/perforation is defined as the development of a significant pericardial
effusion during or within 30 days of undergoing an AF ablation procedure. A significant
pericardial effusion is one that results in hemodynamic compromise, requires elective or
urgent pericardiocentesis, or results in a 1-cm or more pericardial effusion as documented by
echocardiography. Cardiac tamponade/perforation should also be classified as “early” or
“late” depending on whether it is diagnosed during or following initial discharge from the
hospital.
Deep sternal wound infection/mediastinitis
following cardiac surgery
Deep sternal wound infection/mediastinitis following cardiac surgery requires one of the
following: (1) an organism isolated from culture of mediastinal tissue or fluid; (2) evidence
of mediastinitis observed during surgery; (3) one of the following conditions: chest pain,
sternal instability, or fever (>38°C), in combination with either purulent discharge from the
mediastinum or an organism isolated from blood culture or culture of mediastinal drainage.
Esophageal injury Esophageal injury is defined as an erosion, ulceration, or perforation of the esophagus. The
method of screening for esophageal injury should be specified. Esophageal injury can be a
mild complication (erosion or ulceration) or a major complication (perforation).
Gastric motility/pyloric spasm disorders Gastric motility/pyloric spasm disorder should be considered a major complication of AF
ablation when it prolongs or requires hospitalization, requires intervention, or results in late
disability, such as weight loss, early satiety, diarrhea, or GI disturbance.
Major complication A major complication is a complication that results in permanent injury or death, requires
intervention for treatment, or prolongs or requires hospitalization for more than 48 h.
Because early recurrences of AF/AFL/AT are to be expected following AF ablation,
recurrent AF/AFL/ATwithin 3 months that requires or prolongs a patient's hospitalization
should not be considered to be a major complication of AF ablation.
Mediastinitis Mediastinitis is defined as inflammation of the mediastinum. Diagnosis requires one of the
following: (1) an organism isolated from culture of mediastinal tissue or fluid; (2) evidence
of mediastinitis observed during surgery; (3) one of the following conditions: chest pain,
sternal instability, or fever (>38°C), in combination with either purulent discharge from the
mediastinum or an organism isolated from blood culture or culture of mediastinal drainage.
Myocardial infarction in the context of AF
ablation
The universal definition of myocardial infarction [395] cannot be applied in the context of
catheter or surgical AF ablation procedures because it relies heavily on cardiac biomarkers
(troponin and CPK), which are anticipated to increase in all patients who undergo AF
ablation as a result of the ablation of myocardial tissue. Similarly, chest pain and other
cardiac symptoms are difficult to interpret in the context of AF ablation both because of the
required sedation and anesthesia and also because most patients experience chest pain
following the procedure as a result of the associated pericarditis that occurs following
catheter ablation.We therefore propose that a myocardial infarction, in the context of catheter
or surgical ablation, be defined as the presence of any one of the following criteria: (1)
detection of ECG changes indicative of new ischemia (new ST-T wave changes or new
LBBB) that persist for more than 1 h; (2) development of new pathological Q waves on an
ECG; (3) imaging evidence of new loss of viable myocardium or new regional wall motion
abnormality.
Pericarditis Pericarditis should be considered a major complication following ablation if it results in an
effusion that leads to hemodynamic compromise or requires pericardiocentesis, prolongs
hospitalization by more than 48 h, requires hospitalization, or persists for more than 30 days
following the ablation procedure.
Phrenic nerve paralysis Phrenic nerve paralysis is defined as absent phrenic nerve function as assessed by a sniff test. A
phrenic nerve paralysis is considered to be permanent when it is documented to be present 12
months or longer following ablation.
20 J Interv Card Electrophysiol (2017) 50:1–55
multicenter clinical trials. It is as a result of these trials that
conventional thinking about the best techniques, success rates,
complication rates, and long-term outcomes beyond AF recur-
rence—such as thromboembolism and mortality—is being
put to the test. The ablation literature has also seen a prolifer-
ation of meta-analyses and other aggregate analyses, which
reinforce the need for consistency in the approach to reporting
the results of clinical trials. This section reviews the minimum
requirements for reporting on AF ablation trials. It also ac-
knowledges the potential limitations of using specific primary
outcomes and emphasizes the need for broad and consistent
reporting of secondary outcomes to assist the end-user in de-
termining not only the scientific, but also the clinical relevance
of the results (Tables 10, 11, 12, and 13).
Table 8 (continued)
Pulmonary vein stenosis Pulmonary vein stenosis is defined as a reduction of the diameter of a PVor PV branch.
PV stenosis can be categorized as mild <50%, moderate 50%–70%, and severe ≥70%
reduction in the diameter of the PVor PV branch. A severe PV stenosis should be
considered a major complication of AF ablation.
Serious adverse device effect A serious adverse device effect is defined as a serious adverse event that is attributed to
use of a particular device.
Stiff left atrial syndrome Stiff left atrial syndrome is a clinical syndrome defined by the presence of signs of right
heart failure in the presence of preserved LV function, pulmonary hypertension (mean PA
pressure >25 mmHg or during exercise >30 mmHg), and large V waves ≥10 mmHg or
higher) on PCWP or left atrial pressure tracings in the absence of significant mitral valve
disease or PV stenosis.
Stroke or TIA postablation Stroke diagnostic criteria
•Rapid onset of a focal or global neurological deficit with at least one of the following:
change in level of consciousness, hemiplegia, hemiparesis, numbness or sensory loss
affecting one side of the body, dysphasia or aphasia, hemianopia, amaurosis fugax, or
other neurological signs or symptoms consistent with stroke
•Duration of a focal or global neurological deficit ≥24 h; OR <24 h if therapeutic
intervention(s) were performed (e.g., thrombolytic therapy or intracranial angioplasty);
OR available neuroimaging documents a new hemorrhage or infarct; OR the neurological
deficit results in death.
•No other readily identifiable nonstroke cause for the clinical presentation (e.g., brain
tumor, trauma, infection, hypoglycemia, peripheral lesion, pharmacological influences).∗
•Confirmation of the diagnosis by at least one of the following: neurology or
neurosurgical specialist; neuroimaging procedure (MRI or CT scan or cerebral
angiography); lumbar puncture (i.e., spinal fluid analysis diagnostic of intracranial
hemorrhage)
Stroke definitions
• Transient ischemic attack: new focal neurological deficit with rapid symptom resolution
(usually 1 to 2 h), always within 24 h; neuroimaging without tissue injury
•Stroke: (diagnosis as above, preferably with positive neuroimaging study);
Minor—Modified Rankin score <2 at 30 and 90 days†
Major—Modified Rankin score ≥2 at 30 and 90 days
Unanticipated adverse device effect Unanticipated adverse device effect is defined as complication of an ablation procedure
that has not been previously known to be associated with catheter or surgical ablation
procedures.
Vagal nerve injury Vagal nerve injury is defined as injury to the vagal nerve that results in esophageal
dysmotility or gastroparesis. Vagal nerve injury is considered to be a major complication
if it prolongs hospitalization, requires hospitalization, or results in ongoing symptoms for
more than 30 days following an ablation procedure.
Vascular access complication Vascular access complications include development of a hematoma, an AV fistula, or a
pseudoaneurysm. A major vascular complication is defined as one that requires
intervention, such as surgical repair or transfusion, prolongs the hospital stay, or requires
hospital admission.
AF atrial fibrillation, CT computed tomography,MRImagnetic resonance imaging, PRBC packed red blood cell, AFL atrial flutter, AT atrial tachycardia,
CPK creatine phosphokinase, ECG electrocardiogram, LBBB left bundle branch block
∗Patients with nonfocal global encephalopathy will not be reported as a stroke without unequivocal evidence based on neuroimaging studies
†Modified Rankin score assessments should bemade by qualified individuals according to a certification process. If there is discordance between the 30-
and 90-day modified Rankin scores, a final determination of major versus minor stroke will be adjudicated by the neurology members of the clinical
events committee
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13.1 Unanswered questions in AF ablation
There is still much to be learned about the mechanisms of AF,
techniques of AF ablation, and long-term outcomes. The fol-
lowing are unanswered questions for future investigation:
1 AF ablation and modification of stroke risk and need for
ongoing oral anticoagulation (OAC): The CHA2DS2-
VASc score was developed for patients with clinical
AF. If a patient has received a successful ablation such
that he/she no longer has clinical AF (subclinical, or no
Table 9 Incidence, prevention, diagnosis, and treatment of selected complications of AF ablation
Complication Incidence Selected prevention techniques Diagnostic testing Selected treatment options References
Air embolism <1% Sheath management Nothing or cardiac
catheterization
Supportive care with fluid,
oxygen, head down tilt,
hyperbaric oxygen
[388, 396–401]
Asymptomatic
cerebral emboli
(ACE)
2% to
15%
Anticoagulation, catheter and sheath
management, TEE
Brain MRI None [402–419]
Atrial esophageal
fistula
0.02% to
0.11%
Reduce power, force, and RF time
on posterior wall, monitor
esophageal temp, use proton
pump inhibitors; avoid energy
delivery over esophagus
CT scan of chest, MRI;
avoid endoscopy with
air insufflation
Surgical repair [337–365, 420–456]
Cardiac
tamponade
0.2% to
5%
Cather manipulation, transseptal
technique, reduce power, force,
and RF time
Echocardiography Pericardiocentesis or
surgical drainage
[338, 343, 347,
457–467]
Coronary artery
stenosis/-
occlusion
<0.1% Avoid high-power energy delivery
near coronary arteries
Cardiac catheterization PTCA [468–476]
Death <0.1% to
0.4%
Meticulous performance of
procedure, attentive
postprocedure care
NA NA [338, 343, 347, 458,
477]
Gastric
hypomotility
0% to
17%
Reduce power, force, and RF time
on posterior wall
Endoscopy, barium
swallow, gastric
emptying study
Metoclopramide, possibly
intravenous
erythromycin
[478–490]
Mitral valve
entrapment
<0.1% Avoid circular catheter placement
near or across mitral valve;
clockwise torque on catheter
Echocardiography Gentle catheter
manipulation, surgical
extraction
[491–498]
Pericarditis 0% to
50%
None proven Clinical history, ECG,
sedimentation rate,
echocardiogram
NSAID, colchicine,
steroids
[499–506]
Permanent
phrenic nerve
paralysis
0% to
0.4%
Monitor diaphragm during phrenic
pacing, CMAP monitoring,
phrenic pacing to identify location
and adjust lesion location
CXR, sniff test Supportive care [9, 11, 156, 347, 367,
446, 457, 478,
479, 487–490,
507–528]
Pulmonary vein
stenosis
<1% Avoid energy delivery within PV CTorMRI, V/Q wave scan Angioplasty, stent, surgery [9, 11, 313, 316–335,
457, 529–531]
Radiation injury <0.1% Minimize fluoroscopy exposure,
especially in obese and repeat
ablation patients, X-ray
equipment
None Supportive care, rarely skin
graft
[513, 532–550]
Stiff left atrial
syndrome
<1.5% Limit extent of left atrial ablation Echocardiography, cardiac
catheterization
Diuretics [551–558]
Stroke and TIA 0% to 2% Pre-, post-, and intraprocedure
anticoagulation, catheter and
sheath management, TEE
Head CT or MRI, cerebral
angiography
Thrombolytic therapy,
angioplasty
[10–13, 338, 347,
367, 458,
559–565]
Vascular
complications
0.2% to
1.5%
Vascular access techniques,
ultrasound-guided access,
anticoagulation management
Vascular ultrasound, CT
scan
Conservative treatment,
surgical repair,
transfusion
[338, 347, 371, 373,
374, 380, 458,
511, 566–575]
AF atrial fibrillation, CT computed tomography, MRI magnetic resonance imaging, TEE transesophageal electrocardiogram, RF radiofrequency, PTCA
percutaneous transluminal coronary angioplasty, NA not applicable, ECG electrocardiogram, NSAID nonsteroidal anti-inflammatory drug, CMAP
compound motor action potentials, CXR chest X-ray, TIA transient ischemic attack
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Table 10 Definitions for use when reporting outcomes of AF ablation and in designing clinical trials of catheter or surgical ablation of AF
Acute procedural success (pulmonary vein
isolation)
Acute procedural success is defined as electrical isolation of all pulmonary veins. A
minimal assessment of electrical isolation of the PVs should consist of an assessment
of entrance block. If other methods are used to assess PVI, including exit block and/or
the use of provocative agents such as adenosine or isoproterenol, they should be
prespecified. Furthermore, it is recommended that the wait time used to screen for early
recurrence of PV conduction once initial electrical isolation is documented be specified
in all prospective clinical trials.
Acute procedural success (not related by
pulmonary vein isolation)
Typically, this would apply to substrate ablation performed in addition to PVI for
persistent AF. Although some have proposed AF termination as a surrogate for acute
procedural success, its relationship to long-term success is controversial. Complete
elimination of the additional substrate (localized rotational activation, scar region,
non-PV trigger, or other target) and/or demonstration of bidirectional conduction block
across a linear ablation lesion would typically be considered the appropriate endpoint.
One-year success∗ One-year success is defined as freedom from AF/AFL/AT after removal from
antiarrhythmic drug therapy as assessed from the end of the 3month blanking period to
12 months following the ablation procedure. Because cavotricuspid
isthmus-dependent atrial flutter is easily treated with cavotricuspid isthmus ablation
and is not an iatrogenic arrhythmia following a left atrial ablation procedure for AF, it is
reasonable for clinical trials to choose to prespecify that occurrence of
isthmus-dependent atrial flutter, if confirmed by entrainment maneuvers during
electrophysiology testing, should not be considered an ablation failure or primary
effectiveness endpoint.
Alternative one-year success Although the one-year success definition provided above remains the recommended end
point that should be reported in all AF ablation trials, and the endpoint for which the
objective performance criteria listed below were developed, the Task Force recognizes
that alternative definitions for success can be used if the main goal of therapy in the
study is to relieve AF-related symptoms and to improve patient QOL. In particular, it is
appropriate for clinical trials to define success as freedom from only symptomatic
AF/AFL/AT after removal from antiarrhythmic drug therapy as assessed from the end
of the 3-month blanking period to 12 months following the ablation procedure if the
main goal of therapy in the study is to relieve AF-related symptoms and to improve
patient QOL. However, because symptoms of AF can resolve over time, and because
studies have shown that asymptomatic AF represents a greater proportion of all AF
postablation than prior to ablation, clinical trials need to continue to report freedom
from both symptomatic and asymptomatic AF even if this alternative one year success
definition is used as the primary trial endpoint.
Clinical/partial success∗ It is reasonable for clinical trials to define and incorporate one or more secondary
definitions of success that can be referred to as “clinical success” or “partial success.” If
these alternative definitions of success are included, they should be defined
prospectively. In prior Consensus Documents the Task Force has proposed that
clinical/partial success be defined as a “75% or greater reduction in the number of AF
episodes, the duration of AF episodes, or the % time a patient is in AF as assessed with
a device capable of measuring AF burden in the presence or absence of previously
ineffective antiarrhythmic drug therapy.” Because there is no firm scientific basis for
selecting the cutoff of 75% rather than a different cutoff, this prior recommendation is
provided only as an example of what future clinical trials may choose to use as a
definition of clinical/partial success.
Long-term success∗ Long-term success is defined as freedom from AF/AFL/AT recurrences following the
3-month blanking period through a minimum of 36-month follow-up from the date of
the ablation procedure in the absence of Class I and III antiarrhythmic drug therapy.
Recurrent AF/AFL/AT Recurrent AF/AFL/AT is defined as AF/AFL/AT of at least 30 s' duration that is
documented by an ECG or device recording system and occurs following catheter
ablation. Recurrent AF/AFL/AT may occur within or following the post ablation
blanking period. Recurrent AF/AFL/AT that occurs within the postablation blanking
period is not considered a failure of AF ablation.
Early recurrence of AF/AFL/AT Early recurrence of AF/AFL/AT is defined as a recurrence of atrial fibrillation within
three months of ablation. Episodes of atrial tachycardia or atrial flutter should also be
classified as a “recurrence.” These are not counted toward the success rate if a blanking
period is specified.
Recurrence of AF/AFL/AT Recurrence of AF/AFL/AT postablation is defined as a recurrence of atrial fibrillation
more than 3 months following AF ablation. Episodes of atrial tachycardia or atrial
flutter should also be classified as a “recurrence.”
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Table 10 (continued)
Late recurrence of AF/AFL/AT Late recurrence of AF/AFL/AT is defined as a recurrence of atrial fibrillation 12 months
or more after AF ablation. Episodes of atrial tachycardia or atrial flutter should also be
classified as a “recurrence.”
Blanking period A blanking period of three months should be employed after ablation when reporting
efficacy outcomes. Thus, early recurrences of AF/AFL/AT within the first 3 months
should not be classified as treatment failure. If a blanking period of less than 3 months is
chosen, it should be prespecified and included in the Methods section.
Stroke screening A risk-based approach to determine the level of postablation stroke screening in clinical
trials is recommended by the Task Force. For ablation devices with a lower risk of stroke
and for which a stroke signal has not been reported, a minimum standardized neurological
assessment of stroke should be conducted by a physician at baseline and at hospital
discharge or 24 h after the procedure, whichever is later. If this neurological assessment
demonstrates new abnormal findings, the patient should have a formal neurological
consult and examination with appropriate imaging (i.e., DW-MRI), used to confirm any
suspected diagnosis of stroke. For devices in which a higher risk of stroke is suspected or
revealed in prior trials, a formal neurological examination by a neurologist at discharge or
24 h after the procedure, whichever is later, is recommended. Appropriate imaging should
be obtained if this evaluation reveals a new neurological finding. In some studies inwhich
delayed stroke is a concern, repeat neurological screening at 30 days postablation might
be appropriate.
Detectable AF/AFL/AT Detectable AF is defined as AF/AFL/AT of at least 30 s' duration when assessed with
ECG monitoring. If other monitoring systems are used, including implantable
pacemakers, implantable defibrillators, and subcutaneous ECG monitoring devices, the
definition of detectable AF needs to be prespecified in the clinical trial based on the
sensitivity and specificity of AF detection with the particular device. We recommend that
episodes of atrial flutter and atrial tachycardia be included within the broader definition of
a detectable AF/AFL/AT episode.
AF/AFL/AT burden It is reasonable for clinical trials to incorporate AF/AFL/AT burden as a secondary
endpoint in a clinical trial of AF ablation. In stating this it is recognized that there are no
conclusive data that have validated a rate of AF burden reduction as a predictor of patient
benefit (i.e. reduction in mortality and major morbidities such as stroke, CHF, QOL, or
hospitalization). If AF burden is included, it is important to predefine and standardize the
monitoring technique that will be used to measure AF burden. Available monitoring
techniques have been discussed in this document. Should AF burden be selected as an
endpoint in a clinical trial, the chosen monitoring technique should be employed at least a
month prior to ablation to establish a baseline burden of AF.
Entrance block Entrance block is defined as the absence, or if present, the dissociation, of electrical
activity within the PV antrum. Entrance block is most commonly evaluated using a
circular multielectrode mapping catheter positioned at the PVantrum. Entrance block can
also be assessed using detailed point-by-point mapping of the PVantrum guided by an
electroanatomical mapping system. The particular method used to assess entrance block
should be specified in all clinical trials. Entrance block of the left PVs should be assessed
during distal coronary sinus or left atrial appendage pacing in order to distinguish far-field
atrial potentials from PV potentials. It is recommended that reassessment of entrance
block be performed a minimum of 20 min after initial establishment of PV isolation.
Procedural endpoints for AF ablation
strategies not targeting the PVs
Procedural endpoints for AF ablation strategies not targeting the PVs: The acute
procedural endpoints for ablation strategies not targeting the PVs vary depending on the
specific ablation strategy and tool. It is important that they be prespecified in all clinical
trials. For example, if a linear ablation strategy is used, documentation of bidirectional
block across the ablation line must be shown. For ablation of CFAEs, rotational activity,
or non-PV triggers, the acute endpoint should at a minimum be elimination of CFAEs,
rotational activity, or non-PV triggers. Demonstration of AF slowing or termination is an
appropriate procedural endpoint, but it is not required as a procedural endpoint for AF
ablation strategies not targeting the PVs.
Esophageal temperature monitoring Esophageal temperature monitoring should be performed in all clinical trials of AF
ablation. At a minimum, a single thermocouple should be used. The location of the probe
should be adjusted during the procedure to reflect the location of energy delivery.
Although this document does not provide formal recommendations regarding the specific
temperature or temperature change at which energy delivery should be terminated, the
Task Force does recommend that all trials prespecify temperature guidelines for
termination of energy delivery.
Enrolled subject An enrolled subject is defined as a subject who has signed written informed consent to
participate in the trial in question.
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Exit block Exit block is defined as the inability to capture the atrium during pacing at multiple sites
within the PVantrum. Local capture of musculature within the pulmonary veins and/or
antrum must be documented to be present to make this assessment. Exit block is
demonstrated by a dissociated spontaneous pulmonary vein rhythm.
Nonablative strategies The optimal nonablative therapy for patients with persistent and long-standing persistent
AF who are randomized to the control arm of an AF ablation trial is a trial of a newClass I
or III antiarrhythmic agent or a higher dose of a previously failed antiarrhythmic agent.
For patients with persistent or long-standing persistent AF, performance of a direct-
current cardioversion while taking the new or dose adjusted antiarrhythmic agent should
be performed, if restoration of sinus rhythm is not achieved following initiation and/or
dose adjustment of antiarrhythmic drug therapy. Failure of pharmacological
cardioversion alone is not adequate to declare this pharmacological strategy unsuccessful.
Noninducibility of atrial fibrillation Noninducibility of atrial fibrillation is defined as the inability to induce atrial fibrillation
with a standardized prespecified pharmacological or electrical stimulation protocol. The
stimulation protocol should be prespecified in the specific clinical trial. Common
stimulation approaches include a high-dose isoproterenol infusion protocol or repeated
atrial burst pacing at progressively more rapid rates.
Patient populations for inclusion in clinical
trials
It is considered optimal for clinical trials to enroll patients with only one type of AF:
paroxysmal, persistent, or long-standing persistent. If more than one type of AF patient is
enrolled, the results of the trial should also be reported separately for each of the AF types.
It is recognized that “early persistent” AF responds to AF ablation to a similar degree as
patients with paroxysmal AF and that the response of patients with “late persistent AF” is
more similar to that in those with long-standing persistent AF.
Therapy consolidation period Following a 3-month blanking period, it is reasonable for clinical trials to incorporate an
additional 1- to 3-month therapy consolidation period. During this time, adjustment of
antiarrhythmic medications and/or cardioversion can be performed. Should a
consolidation period be incorporated into a clinical trial design, the minimum follow-up
duration should be 9 months following the therapy consolidation period. Performance of
a repeat ablation procedure during the blanking or therapy consolidation period would
“reset” the endpoint of the study and trigger a new 3-month blanking period.
Incorporation of a therapy consolidation period can be especially appropriate for clinical
trials evaluating the efficacy of AF ablation for persistent or long-standing persistent AF.
The challenge of this approach is that it prolongs the overall study duration. Because of
this concern regarding overall study duration, we suggest that the therapy consolidation
period be no more than 3 months in duration following the 3-month blanking period.
Recommendations regarding repeat ablation
procedures
It is recommended that all clinical trials report the single procedure efficacy of catheter
ablation. Success is defined as freedom from symptomatic or asymptomatic AF/AFL/AT
of 30 s or longer at 12months postablation. Recurrences of AF/AFL/AT during the first 3-
month blanking period post-AF ablation are not considered a failure. Performance of a
repeat ablation procedure at any point after the initial ablation procedure should be
considered a failure of a single procedure strategy. It is acceptable for a clinical trial to
choose to prespecify and use a multiprocedure success rate as the primary endpoint of a
clinical trial. When a multiprocedure success is selected as the primary endpoint, efficacy
should be defined as freedom from AF/flutter or tachycardia at 12 months after the final
ablation procedure. In the case of multiple procedures, repeat ablation procedures can be
performed at any time following the initial ablation procedure. All ablation procedures
are subject to a 3-month post blanking window, and all ablation trials should report
efficacy at 12 months after the final ablation procedure.
Cardioversion definitions
Failed electrical cardioversion Failed electrical cardioversion is defined as the inability to restore sinus rhythm for 30 s or
longer following electrical cardioversion.
Successful electrical cardioversion Successful electrical cardioversion is defined as the ability to restore sinus rhythm for at
least 30 s following cardioversion.
Immediate AF recurrence
postcardioversion
Immediate AF recurrence postcardioversion is defined as a recurrence of AF within 24 h
following cardioversion. The most common time for an immediate recurrence is within
30–60 min postcardioversion.
Early AF recurrence postcardioversion Early AF recurrence postcardioversion is defined as a recurrence of AF within 30 days of
a successful cardioversion.
Late AF recurrence postcardioversion Late AF recurrence postcardioversion is defined as recurrence of AF more than 30 days
following a successful cardioversion.
Surgical ablation definitions
Hybrid AF surgical ablation procedure Hybrid AF surgical ablation procedure is defined as a joint AF ablation procedure
performed by electrophysiologists and cardiac surgeons either as part of a single “joint”
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procedure or performed as two preplanned separate ablation procedures separated by no
more than 6 months.
Surgical Maze ablation procedure Surgical Maze ablation procedure is defined as a surgical ablation procedure for AF that
includes, at a minimum, the following components: (1) line from SVC to IVC; (2) line
from IVC to the tricuspid valve; (3) isolation of the PVs; (4) isolation of the posterior left
atrium; (5) line from MV to the PVs; (6) management of the LA appendage.
Stand-alone surgical AF ablation A surgical AF ablation procedure during which other cardiac surgical procedures are not
performed such as CABG, valve replacement, or valve repair.
Nomenclature for types of surgical AF
ablation procedures
We recommend that the term “Maze” procedure is appropriately used only to refer to the
biatrial lesion set of the Cox-Maze operation. It requires ablation of the RA and LA
isthmuses. Less extensive lesion sets should not be referred to as a “Maze” procedure, but
rather as a surgical AF ablation procedure. In general, surgical ablation procedures for AF
can be grouped into three different groups: (1) a full biatrial Cox-Maze procedure; (2) PVI
alone; and (3) PVI combined with left atrial lesion sets.
Hybrid epicardial and endocardial AF
ablation
This term refers to a combined AF ablation procedure involving an off-pump minimally
invasive surgical AF ablation as well as a catheter-based AF ablation procedure designed
to complement the surgical lesion set. Hybrid ablation procedures may be performed in a
single-procedure setting in a hybrid operating room or a cardiac catheterization laboratory
environment, or it can be staged. When staged, it is most typical to have the patient
undergo the minimally invasive surgical ablation procedure first following by a catheter
ablation procedure 1 to 3 months later. This latter approach is referred to as a “staged
Hybrid AF ablation procedure.”
Minimum AF documentation, endpoints, TEE performance, and success rates in clinical trials
Minimum documentation for paroxysmal
AF
The minimum AF documentation requirement for paroxysmal AF is (1) physician's note
indicating recurrent self-terminating AF and (2) one electrocardiographically
documented AF episode within 6 months prior to the ablation procedure.
Minimum documentation for persistent AF The minimum AF documentation requirement for persistent AF is (1) physician's note
indicating continuousAF >7 days but nomore than 1 year and (2) a 24-h Holter within 90
days of the ablation procedure showing continuous AF.
Minimum documentation for early
persistent AF
The minimum AF documentation requirement for persistent AF is (1) physician's note
indicating continuous AF >7 days but no more than 3 months and (2) a 24-h Holter
showing continuous AF within 90 days of the ablation procedure.
Minimum documentation for long-standing
persistent AF
The minimum AF documentation requirement for long-standing persistent AF is as
follows: physician's note indicating at least 1 year of continuous AF plus a 24-h Holter
within 90 days of the ablation procedure showing continuous AF. The performance of a
successful cardioversion (sinus rhythm >30 s) within 12 months of an ablation procedure
with documented early recurrence of AF within 30 days should not alter the classification
of AF as long-standing persistent.
Symptomatic AF/AFL/AT AF/AFL/AT that results in symptoms that are experienced by the patient. These
symptoms can include but are not limited to palpitations, presyncope, syncope, fatigue,
and shortness of breath. For patients in continuous AF, reassessment of symptoms after
restoration of sinus rhythm is recommended to establish the relationship between
symptoms and AF.
Documentation of AF-related symptoms Documentation by a physician evaluating the patient that the patient experiences
symptoms that could be attributable to AF. This does not require a time-stamped ECG,
Holter, or event monitor at the precise time of symptoms. For patients with persistent AF
who initially report no symptoms, it is reasonable to reassess symptom status after
restoration of sinus rhythm with cardioversion.
Minimum effectiveness endpoint for
patients with symptomatic and asymptomatic
AF
The minimum effectiveness endpoint is freedom from symptomatic and asymptomatic
episodes of AF/AFL/AT recurrences at 12 months following ablation, free from
antiarrhythmic drug therapy, and including a prespecified blanking period.
Minimum chronic acceptable success rate:
paroxysmal AF at 12-month follow-up
If a minimum chronic success rate is selected as an objective effectiveness endpoint for a
clinical trial, we recommend that the minimum chronic acceptable success rate for
paroxysmal AF at 12-month follow-up is 50%.
Minimum chronic acceptable success rate:
persistent AF at 12-month follow-up
If a minimum chronic success rate is selected as an objective effectiveness endpoint for a
clinical trial, we recommend that the minimum chronic acceptable success rate for
persistent AF at 12-month follow-up is 40%.
Minimum chronic acceptable success rate:
long-standing persistent AF at 12-month
follow-up
If a minimum chronic success rate is selected as an objective effectiveness endpoint for a
clinical trial, we recommend that the minimum chronic acceptable success rate for long-
standing persistent AF at 12-month follow-up is 30%.
Minimum follow-up screening for
paroxysmal AF recurrence
For paroxysmal AF, the minimum follow-up screening should include (1) 12-lead ECG at
each follow-up visit; (2) 24-h Holter at the end of the follow-up period (e.g., 12 months);
and (3) event recording with an event monitor regularly and when symptoms occur from
the end of the 3-month blanking period to the end of follow-up (e.g., 12 months).
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AF), then what is the need for ongoing OAC? Are there
any patients in whom successful ablation could lead to
discontinuation of OAC?
2 Substrate modification in catheter-based manage-
ment of AF—particularly for persistent AF: What
is the proper lesion set required beyond pulmonary
vein isolation? Do lines and complex fractionated
atrial electrogram (CFAE) have any remaining role?
Are these approaches ill-advised or simply discour-
aged?
What is the role of targeting localized rotational
activations? How do we ablate a localized rotation-
al activation? How can scar be characterized and
targeted for ablation? Do we need to replicate the
MAZE procedure? Does the right atrium need to be
targeted as well as the left atrium?
3 Autonomic influence in AF: Is clinical AF really an
autonomic mediated arrhythmia? Is elimination of
ganglionated plexi required? Is there a role for au-
tonomic modulation, for example, spinal cord or
vagal stimulation?
4 Contribution and modulation of risk factors on out-
comes of AF ablation: Obesity reduction has been
shown to reduce AF burden and recurrence in pa-
tients undergoing ablation. What is the role of bar-
iatric surgery? Does the modulation of other risk
factors influence outcome such as hypertension,
sleep apnea, and diabetes?
5 Outcomes in ablation of high-risk populations: Do high-
risk populations benefit from AF ablation? Congestive
heart failure has been assessed in smaller trials, but larger
trials are required. Outcome data are needed in patients
with very enlarged LAs, hypertrophic cardiomyopathy,
patients with renal failure on dialysis, and the very
elderly.
6 Surgical vs catheter-based vs hybrid ablation: There
should be more comparative work between percuta-
neous and minimally invasive surgical approaches.
Both report similar outcomes, but there is a dearth
of comparative data. Is there any patient benefit to
hybrid procedures?
7 How do we characterize patients who are optimal
candidates for ablation? Preablation late gadolinium-
enhanced (LGE)-magnetic resonance imaging (MRI)
might identify patients with heavy burdens of scar
who are unlikely to respond to ablation. These tech-
niques must become reproducible and reliable and
must be assessed in multicenter trials. Other markers
need to be investigated, including genetic markers,
biochemical markers, and clinical markers based on
aggregated risk scores.
8 The incremental role of new technologies: As
newer and often more expensive technologies are
produced for AF ablation, their definitive incremen-
tal value must be determined in order to justify
change in practice or case cost. These technologies
include global (basket) mapping techniques, newer
ablation indices for assessing lesion durability, ad-
vanced imaging for viewing lesions in the myocar-
dium, etc. New energy sources, including laser,
low-intensity ultrasound, photonic particle therapy,
external beam ablation, and MRI-guided ablation,
must be assessed in comparative fashion.
9 Outcomes of AF ablation: We need to better under-
stand the clinical relevance of ablation outcomes.
What is the significance of time to recurrence of
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Minimum follow-up screening for
persistent or long-standing AF recurrence
For persistent and long-standing persistent AF, the minimum follow-up screening should
include (1) 12-lead ECG at each follow-up visit; (2) 24-h Holter every 6 months; and (3)
symptom-driven event monitoring.
Requirements for transesophageal
echocardiogram
It is recommended that the minimum requirement for performance of a TEE in a clinical
trial should be those requirements set forth in ACC/AHA/HRS 2014 Guidelines for AF
Management pertaining to anticoagulation at the time of cardioversion. Prior to
undergoing an AF ablation procedure a TEE should be performed in all patients with AF
of >48 h' duration or of unknown duration if adequate systemic anticoagulation has not
been maintained for at least 3 weeks prior to AF ablation. If a TEE is performed for this
indication, it should be performed within 24 h of the ablation procedure.
AF atrial fibrillation, DW-MRI diffusion-weighted magnetic resonance imaging, CHF congestive heart failure, QOL quality of life, ECG electrocar-
diogram, CABG coronary artery bypass grafting, PV pulmonary vein, SVC superior vena cava, IVC inferior vena cava,CFAE complex fractionated atrial
electrogram, PVI pulmonary vein isolation, AFL atrial flutter, AT atrial tachycardia, ACC American College of Cardiology, AHA American Heart
Association, HRS Heart Rhythm Society
∗When reporting outcomes of AF ablation, the development of atrial tachycardia or atrial flutter should be included in the broad definition of recurrence
following AF ablation. All studies should report freedom from AF, atrial tachycardia, and atrial flutter. These endpoints can also be reported separately.
All studies should also clearly specify the type and frequency of ECG monitoring as well as the degree of compliance with the prespecified monitoring
protocol
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Table 11 Quality-of-life scales, definitions, and strengths
Scale Definition/Details Strengths/Weaknesses
Short Form (36) Health
Survey
(SF36)38(General)
Consists of 8 equally weighted, scaled scores in the
following sections: vitality, physical functioning,
bodily pain, general health perceptions, physical role
functioning, emotional role functioning, social role
functioning, mental health. Each section receives a
scale score from 0 to 100.Physical component
summary (PCS) and mental component summary
(MCS) is an average of all the physically and
mentally relevant questions, respectively.The Short
Form (12) Health Survey (SF12) is a shorter version
of the SF-36, which uses just 12 questions and still
provides scores that can be compared with SF-36
norms, especially for summary physical and mental
functioning.Gives more precision in measuring
QOL than EQ-5D but can be harder to transform into
cost utility analysis.
Advantages: extensively validated in a number of
disease and health states. Might have more
resolution than EQ-50 for AF QOL.Disadvantages:
not specific for AF, so might not have resolution to
detect AF-specific changes in QOL.
EuroQol Five Dimensions
Questionnaire
(EQ-5D)39(General)
Two components: Health state description is measured
in five dimensions: mobility, self-care, usual
activities, pain/discomfort, anxiety/depression.
Answers may be provided on a three-level (3L) or
five-level (5L) scale. In the Evaluation section,
respondents evaluate their overall health status using
a visual analogue scale (EQ-VAS). Results can easily
be converted to quality-adjusted life years for cost
utility analysis.
Advantages: extensively validated in a number of
disease and health states. Can easily be converted
into quality-adjusted life years for cost-effectiveness
analysis.Disadvantages: might not be specific
enough to detect AF-specific changes in QOL.
Might be less specific than SF-36.
AF effect on Quality of
Life Survey (AFEQT)40
(AF specific)
20 questions: 4 targeting AF-related symptoms, 8
evaluating daily function, and 6 assessing AF
treatment concerns. Each item scored on a 7-point
Likert scale.
Advantages: brief, simple, very responsive to AF
interventions. Good internal validity and well
validated against a number of other global and
AF-specific QOL scales. Used in
CABANA.Disadvantages: validation in only two
published studies (approximately 219 patients).
Quality of Life
Questionnaire for
Patients with
AF(AF-QoL)41(AF
specific)
18-item self-administered questionnaire with three
domains: psychological, physical, and sexual
activity. Each item scores on a 5-point Likert scale.
Advantages: brief, simple, responsive to AF
interventions; good internal validity; used in SARA
trial.Disadvantages: external validity compared only
to SF-36; formal validation in 1 study
(approximately 400 patients).
Arrhythmia-Related
Symptom Checklist
(SCL)42 (AF specific)
16 items covering AF symptom frequency and
symptom severity.
Advantages: most extensively validated in a number of
arrhythmia cohorts and clinical trials.Disadvantages:
time-consuming and uncertain generalizability.
Mayo AF Specific
Symptom Inventory
(MAFSI)43 (AF
specific)
10 items covering AF symptom frequency and severity.
Combination of 5- point and 3-point Likert scale
responses.Used in CABANA trial.
Advantages: validated in an AF ablation population
and responsive to ablation outcome; used in
CABANA trial.Disadvantages: external validity
compared only to SF-36; 1 validation study
(approximately 300 patients).
University of Toronto
Atrial Fibrillation
Severity Scale (AFSS)
(AF specific)44
10 items covering frequency, duration, and severity.
7-point Likert scale responses.
Advantages: validated and reproducible; used in CTAF
trial.Disadvantages: time-consuming and uncertain
generalizability.
Arrhythmia Specific
Questionnaire in
Tachycardia and
Arrhythmia (ASTA)45
(AF specific)
Records number of AF episodes and average episode
duration during last 3 months. 8 symptoms and 2
disabling symptoms are recorded with scores from
1–4 for each.
Advantages: validated in various arrhythmia groups;
external validity compared with SCL, EQ5D, and
SF-36; used in MANTRA-PAF; brief;
simple.Disadvantages: one validation study
(approximately 300 patients).
European Heart Rhythm
Association (EHRA)46
(AF specific)
Like NYHA scale. I = no symptoms, II = mild
symptoms not affecting daily activity, III = severe
symptoms affecting daily activity, and IV =
disabling symptoms terminating daily activities.
Advantage: very simple, like NYHA.Disadvantages:
not used in studies and not well validated; not very
specific; unknown generalizability.
Canadian Cardiovascular
Society Severity of
Like NYHA scale. O = asymptomatic, I = AF
symptoms have minimal effect on patient's QOL, II
Advantages: very simple, like NYHA; validated
against SF-36 and University of Toronto
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30 s of arrhythmia? How do we best quantify AF
burden? How do these outcomes relate to quality of
life and stroke risk?
10 What is the role of surgical LA reduction? Does left atrial
appendage (LAA) occlusion or obliteration improve out-
come of persistent AF ablation with an accompanying
reduction in stroke? Does ablation work through atrial size
reduction?What is the incidence of “stiff atrial” syndrome
and does this mitigate the clinical impact of ablation?
11 Working in teams: What is the role of the entire heart
team in AF ablation? Does a team approach achieve bet-
ter outcomes than a “silo” approach?
12 Improving the safety of catheter ablation: As abla-
tion extends to more operators and less experienced
Table 11 (continued)
Scale Definition/Details Strengths/Weaknesses
Atrial Fibrillation Scale
(CCS-SAF)47 (AF
specific)
= AF symptoms have minor effect on patient QOL,
III = symptoms have moderate effect on patient
QOL, IV= AF symptoms have severe effect on
patient QOL.
AFSS.Disadvantages: poor correlation with
subjectiveAF burden; not very specific.
AF atrial fibrillation, QOL quality of life, CABANA Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation, SARA Study of Ablation
Versus antiaRrhythmic Drugs in Persistent Atrial Fibrillation, CTAF Canadian Trial of Atrial Fibrillation, MANTRA-PAF Medical ANtiarrhythmic
Treatment or Radiofrequency Ablation in Paroxysmal Atrial Fibrillation, NYHA New York Heart Association, AFSS atrial fibrillation severity scale
Table 12 Non-AF recurrence–
related endpoints for reporting in
AF ablation trials
Stroke and bleeding endpoints Definitions/Details
Stroke (2014 ACC/AHA Key Data
Elements)
An acute episode of focal or global neurological dysfunction caused
by brain, spinal cord, or retinal vascular injury as a result of
hemorrhage or infarction. Symptoms or signs must persist ≥24 h,
or if documented by CT, MRI or autopsy, the duration of
symptoms/signs may be less than 24 h. Strokemay be classified as
ischemic (including hemorrhagic transformation of ischemic
stroke), hemorrhagic, or undetermined. Stroke disability
measurement is typically performed using the modified Rankin
Scale (mRS).
Transient ischemic attack (2014
ACC/AHA Key Data Elements)
Transient episode of focal neurological dysfunction caused by brain,
spinal cord, or retinal ischemia without acute infarction and with
signs and symptoms lasting less than 24 h.
Major bleeding (ISTH definition) Fatal bleeding AND/OR symptomatic bleeding in a critical area or
organ, such as intracranial, intraspinal, intraocular, retroperitoneal,
intraarticular, pericardial, or intramuscular with compartment
syndrome AND/OR bleeding causing a fall in hemoglobin level of
2 g/dL (1.24 mmol/L) or more, or leading to transfusion of two or
more units of blood.
Clinically relevant nonmajor bleed
(ISTH definition)
An acute or subacute clinically overt bleed that does not meet the
criteria for a major bleed but prompts a clinical response such that
it leads to one of the following: hospital admission for bleeding;
physician-guided medical or surgical treatment for bleeding;
change in antithrombotic therapy (including interruption or
discontinuation).
Minor bleeding (ISTH definition) All nonmajor bleeds. Minor bleeds are further divided into clinically
relevant and not.
Incidence and discontinuation of oral
anticoagulation
The number of patients receiving oral anticoagulation and the type of
oral anticoagulation should be documented at the end of
follow-up. If patients have their oral anticoagulation discontinued,
the number of patients discontinuing, the timing of
discontinuation, and the reasons for discontinuation of oral
anticoagulation, as well as the clinical characteristics and stroke
risk profile of the patients should be reported.
AF atrial fibrillation, CT computed tomography, MRI magnetic resonance imaging
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Table 13 Advantages and disadvantages of AF-related endpoints in AF ablation trials
Endpoint Advantages Disadvantages Relevance and Comments
Freedom from AF/AFL/AT
recurrence “gold standard”
is 30 s
- Has been in use for many years - Can systematically underestimate the
efficacy of AF ablation, particularly
for persistent AF, if 30-s cutoff is
used
- Particularly well suited for
paroxysmal AF outcomes
- Can be used to compare results of
new trials with historical trials
- Reporting of cutoffs other than 30 s
encouraged as secondary endpoints
to better contextualize results
- Sets a high bar for AF elimination - May be reported as proportion of
patients free from arrhythmia or
time to recurrence
Freedom from stroke-relevant
AF/AFL/AT-duration
cutoff of 1 h
- Useful for trials in which interest is
more for prognostic change
conferred by ablation rather than
elimination of all arrhythmias
- No consistent definition of what a
stroke-relevant duration of AF is:
ranges from 6 min to 24 h in
literature
- More than 1 h could be a useful
cutoff based on results of 505 trial
- May be reported as proportion of
patients free from arrhythmia or
time to recurrence
Freedom from AF/AFL/AT
requiring intervention
(emergency visits,
cardioversion, urgent care
visit, reablation, etc.)
- Can provide an endpoint more
relevant to systemic costs of AF
recurrence
-Will overestimate efficacy of ablation
by ignoring shorter episodes not
requiring intervention that still
might be important to quality of life
or stroke
- Determination of what is an
“intervention” must be prespecified
in protocol and biases mitigated to
avoid over- or underintervention in
the trial
- Clinically relevant
Freedom from persistent
AF/AFL/AT-duration
cutoff of 7 days
- Useful for trials assessing additional
substrate modification in persistent
AF
- Can systematically overestimate the
efficacy of AF ablation, particularly
for persistent AF
- Can require continuous monitoring to
definitively assess if episode is >7
days
Freedom fromAF/AFL/ATon
previously ineffective
antiarrhythmic therapy
- If patient maintains sinus rhythm on
previously ineffective drug therapy,
this may be considered a clinically
relevant, successful outcome
- Will increase the success rate
compared with off-drug success
- Postablation drug and dosage of drug
should be identical to preablation
drug and dosage- May not be relevant to patients
hoping to discontinue drug therapy
Significant reduction in AF
burden: >75% reduction
from pre- to postablation
and/or total postablation
burden <12%
- Can be useful in persistent AF
studies, but might not be suited for
early, paroxysmal AF studies
- Ideally requires continuous
monitoring using an implantable
device
- AF burden can be estimated by
intermittent monitoring and
reporting of patient symptoms and
recurrences like a “time in
therapeutic range” report for oral
anticoagulation; see text
- No scientific basic exists showing
that a 75% reduction in AF burden
impacts hard endpoints, including
heart failure, stroke, and mortality
- Could also see 75% reduction in
number and duration of AF
episodes
- Because there is no firm scientific
basis for selecting the cutoff of
75%, this prior recommendation is
provided only as an example of
what future clinical trials may
choose to use as a definition of
clinical/partial success
Prevention in AF progression:
time to first episode of
persistent AF (>7 days)
- Does not assume that total
elimination of AF is required
- Prevention in progression might be
irrelevant for stroke or
thromboembolic outcomes
- Might be useful for specific
populations such as heart failure or
hypertrophic cardiomyopathy, in
which progression to persistent AF
can lead to increased hospitalization
- Well suited for paroxysmal or “early”
AF studies in which goal is to
prevent progression to persistent AF
- Long follow-up time might be
required unless population is
“enriched”
- Can ideally require continuous
implantable monitoring
Regression of AF: reduction
in burden to a given
threshold or conversion of
- Does not assume that total
elimination of AF is required
- Regression endpoint will
overestimate efficacy of AF
ablation
- Could be particularly useful for
long-standing persistent AF
populations with structural heart
disease, heart failure, etc.
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operators, the statistical occurrence of complications
will increase. We need newer techniques to mini-
mize complications and institute standards for oper-
ators to improve the reproducibility of ablation re-
sults and safety profiles at a variety of centers
worldwide.
13 How does catheter ablation affect mortality, stroke, and
hospitalization in broad and selected patient populations
receiving catheter ablation for AF?
14 Management of patients who fail initial attempts at
catheter ablation: Should there be specific criteria
for repeat ablations (e.g., atrial size, body mass in-
dex)? Should patients be referred for surgery for
repeat ablation?
In order to address these and other important ques-
tions in the field of catheter and surgical AF ablation,
we urge investigators to create and participate in multi-
site collaborations and electrophysiology research net-
works with involvement of senior and junior investiga-
tors on the steering committees to push forward the next
phase of AF research. We also urge funding bodies to
support these important initiatives.
14 Conclusion
Catheter ablation of AF is a very commonly performed
procedure in hospitals throughout the world. This
document provides an up-to-date review of the indica-
tions, techniques, and outcomes of catheter and surgical
ablation of AF. Areas for which a consensus can be
reached concerning AF ablation are identified, and a
series of consensus definitions have been developed
for use in future clinical trials of AF ablation. Also
included within this document are recommendations
concerning indications for AF ablation, technical perfor-
mance of this procedure, and training. It is our hope to
improve patient care by providing a foundation for
those involved with care of patients with AF as well
as those who perform AF ablation. It is recognized that
this field continues to evolve rapidly and that this doc-
ument will need to be updated. Successful AF ablation
programs optimally should consist of a cooperative team
of cardiologists, electrophysiologists, and surgeons to
ensure appropriate indications, procedure selection, and
follow-up.
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Table 13 (continued)
Endpoint Advantages Disadvantages Relevance and Comments
persistent to paroxysmal
AF
- Well suited for persistent “late” AF
studies in which goal is to regress to
paroxysmal AF, which might be
easier to control with drug therapy
- Might ideally require continuous
implantable monitoring
- Patients will require ongoing drug
therapy
Acute AF termination during
ablation procedure
- Could provide indication of
successful modification of substrate
responsible for maintaining AF,
most relevant to persistent or
long-standing persistent AF
- Relevance of acute AF termination
has not consistently been shown to
correlate to long-term success
- Intraprocedural administration of
preprocedural oral antiarrhythmics
or intraprocedural intravenous
antiarrhythmics are discouraged
- Limited studies have linked acute AF
termination to long-term success
- Endpoint might not be relevant to
paroxysmal AF patients in whom
AF might terminate spontaneously
- If antiarrhythmics are used, their use
and dosage before and during the
ablation should be clearly
documented
- Studies consider termination as
reversion to sinus rhythm, whereas
others consider reversion to any
regular tachycardia as termination
- Some studies employ administration
of intravenous or oral
antiarrhythmics during ablation that
could cause spontaneous
termination
- Termination to sinus rhythm and
termination to another regular
tachycardia (AT or AFL) should be
separately reported
AF atrial fibrillation, AFL atrial flutter, AT atrial tachycardia
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